Compare GDC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | HELP |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 281.4M |
| IPO Year | N/A | N/A |
| Metric | GDC | HELP |
|---|---|---|
| Price | $2.76 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 35.5K | ★ 1.1M |
| Earning Date | 05-14-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $4.41 |
| 52 Week High | $9.92 | $8.55 |
| Indicator | GDC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 35.50 |
| Support Level | $2.32 | $4.47 |
| Resistance Level | $3.72 | $4.95 |
| Average True Range (ATR) | 0.28 | 0.34 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 14.97 | 7.19 |
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.